Testosterone replacement therapy for men over 35 fails when treated as monotherapy. TRT hormone optimization requires simultaneous management of thyroid function, estrogen conversion, DHT activity, insulin sensitivity, and hypothalamic-pituitary feedback. A 150 mg weekly testosterone enanthate protocol without aromatase modulation, thyroid support, or metabolic monitoring delivers suboptimal results in 60-70% of users within 12 months. This article provides the complete foundational stack: exact compounds, dosing frequencies, blood marker targets, and the mechanisms that determine whether you achieve stable energy and body composition or spend two years chasing symptom relief.
Mechanism
Exogenous testosterone suppresses luteinizing hormone and follicle-stimulating hormone via negative feedback at the hypothalamic-pituitary axis. This eliminates endogenous production within 4-6 weeks of consistent administration. The testosterone ester hydrolyzes to free testosterone, which binds androgen receptors in muscle, adipose, bone, and central nervous system tissue. Concurrently, aromatase enzyme in adipose and liver tissue converts a portion to estradiol, and 5-alpha reductase in prostate, scalp, and skin converts another fraction to dihydrotestosterone.
Three systems determine outcome quality beyond serum testosterone levels. First: thyroid axis function. Thyroid hormone regulates androgen receptor density and metabolic rate. Subclinical hypothyroidism—TSH above 2.5 mIU/L with normal T4—blunts TRT response even when total testosterone reaches 800-1000 ng/dL. Second: estrogen metabolism. Aromatase activity increases with body fat percentage and age. Estradiol levels above 40 pg/mL in men drive water retention, gynecomastia precursor tissue, and mood instability, while levels below 15 pg/mL cause joint pain, low libido, and impaired lipid profiles. Third: insulin sensitivity. Testosterone improves glucose disposal, but without dietary structure or metformin support, visceral adiposity limits androgen receptor activation and increases aromatase substrate.
DHT serves as the primary androgen in prostate, sebaceous glands, and scalp follicles. It binds androgen receptors with 3-5 times greater affinity than testosterone. On TRT, total DHT often rises proportionally, causing benign prostatic hyperplasia symptoms or accelerated androgenic alopecia in predisposed individuals. Managing DHT requires 5-alpha reductase inhibition or topical antagonism, not testosterone dose reduction.
Protocol
Foundational TRT hormone optimization begins with testosterone enanthate or cypionate at 100-200 mg per week, split into two injections to minimize peak-trough fluctuation. 150 mg weekly divided into 75 mg every 3.5 days represents the starting point for most men over 35. Inject subcutaneously with 27-gauge 0.5-inch insulin syringes in the abdomen or ventrogluteal region. This achieves steady-state serum levels by week 4-5, with total testosterone in the 700-1000 ng/dL range and free testosterone at 15-25 ng/dL depending on SHBG.
Aromatase modulation begins with anastrozole at 0.25 mg twice weekly, dosed the same day as testosterone injections. This non-steroidal competitive inhibitor reduces estradiol conversion by approximately 50% at this dose. The alternative is exemestane, a steroidal irreversible inhibitor, at 12.5 mg twice weekly. Exemestane offers superior lipid profiles but lower availability. Do not exceed 0.5 mg anastrozole twice weekly unless estradiol remains above 40 pg/mL after 8 weeks with confirmed compliance.
Thyroid support depends on baseline TSH and free T3 levels. If TSH exceeds 2.5 mIU/L or free T3 falls below mid-range (3.0-3.5 pg/mL), add liothyronine at 12.5 mcg upon waking and 12.5 mcg early afternoon. Liothyronine is pure T3, bypassing the T4-to-T3 conversion that declines with age and stress. If TSH is acceptable but free T3 remains low, the issue is peripheral conversion; add selenium 200 mcg and zinc 30 mg daily before introducing liothyronine. For subclinical hypothyroidism with low-normal free T4, levothyroxine 25-50 mcg daily addresses the root deficit.
Metabolic optimization requires metformin 500 mg twice daily with meals. Metformin activates AMPK, improves insulin sensitivity, and reduces hepatic glucose output. This matters on TRT because improved glucose disposal lowers visceral adiposity, which reduces aromatase activity and inflammatory cytokines that blunt androgen receptor signaling. Berberine at 500 mg three times daily offers a non-prescription alternative with similar AMPK activation but inferior long-term compliance due to GI side effects.
Human chorionic gonadotropin at 250-500 IU twice weekly prevents testicular atrophy and maintains intratesticular testosterone production, preserving fertility and supporting neurosteroid synthesis. Inject subcutaneously on non-testosterone days. HCG is optional for men unconcerned with fertility or testicular volume but provides subjective wellbeing benefits in approximately 40% of users.
Monitoring
Blood work at week 0, week 6, week 12, then quarterly. The complete panel: total testosterone, free testosterone, estradiol (sensitive assay, not immunoassay), DHT, TSH, free T3, free T4, lipid panel (total cholesterol, LDL, HDL, triglycerides), complete blood count (hemoglobin, hematocrit), comprehensive metabolic panel (liver enzymes AST/ALT, kidney function creatinine/eGFR), fasting glucose, HbA1c, and prostate-specific antigen.
Target ranges for optimized TRT hormone optimization: total testosterone 700-1000 ng/dL, free testosterone 15-25 ng/dL, estradiol 20-35 pg/mL, DHT 40-70 ng/dL, TSH 0.5-2.0 mIU/L, free T3 3.2-3.8 pg/mL, hematocrit below 52%, AST/ALT below 40 U/L, fasting glucose 75-90 mg/dL, HbA1c below 5.5%, PSA below 1.5 ng/mL with annual delta under 0.3 ng/mL. Estradiol below 20 pg/mL causes joint pain and reduced libido; reduce anastrozole by 50%. Estradiol above 40 pg/mL causes water retention and emotional lability; increase anastrozole by 0.125 mg per dose.
Hematocrit elevation above 52% requires therapeutic phlebotomy—donate 500 mL whole blood every 8-12 weeks or reduce testosterone dose by 20 mg weekly. Elevated hematocrit increases blood viscosity and cardiovascular event risk. Lipid degradation—LDL above 130 mg/dL or HDL below 40 mg/dL—responds to rosuvastatin 5-10 mg daily or ezetimibe 10 mg daily. Do not discontinue TRT for lipid changes unless LDL exceeds 190 mg/dL despite statin therapy.
Subjective markers matter: morning erections return by week 4-6, energy stabilizes by week 8, body composition changes appear by week 12. If libido remains low with testosterone above 700 ng/dL and estradiol in range, check free T3 and DHT. Low DHT with normal testosterone suggests excessive 5-alpha reductase inhibition or genetic polymorphism.
Risks and Mitigation
Cardiovascular risk increases with hematocrit above 54%, uncontrolled hypertension, or LDL above 160 mg/dL. Mitigate hematocrit with phlebotomy every 8-12 weeks and hydration targeting 3-4 liters daily. Manage blood pressure with telmisartan 40-80 mg daily, which offers additional metabolic benefits via PPAR-gamma activation. Control LDL with rosuvastatin 10 mg daily; TRT typically increases LDL by 10-15% while improving HDL.
Gynecomastia develops when estradiol remains above 40 pg/mL for 12+ weeks or spikes above 60 pg/mL acutely. Prevention requires consistent aromatase inhibitor dosing and estradiol monitoring. If tissue proliferation begins, raloxifene 60 mg daily for 90 days reverses early gynecomastia in 60-70% of cases by blocking estrogen receptors in breast tissue.
Testicular atrophy occurs in 100% of men on TRT without HCG. Atrophy is cosmetic but also eliminates intratesticular testosterone, which supports neurosteroid production and may affect mood. HCG 250 IU three times weekly prevents atrophy completely. Fertility preservation requires HCG at minimum; if fertility becomes a near-term goal, add human menopausal gonadotropin 75 IU three times weekly to restore spermatogenesis.
Sleep apnea worsens in 15-20% of TRT users due to increased neck circumference and altered respiratory drive. Symptoms include morning headaches, daytime fatigue despite adequate sleep duration, and partner-reported apnea episodes. Polysomnography confirms diagnosis; treatment is CPAP therapy. Do not reduce testosterone dose for sleep apnea.
Comparisons
TRT hormone optimization with the full foundational stack versus testosterone monotherapy represents the difference between stable results and perpetual troubleshooting. Monotherapy—testosterone only, no AI, no thyroid support, no metabolic intervention—produces satisfactory outcomes in approximately 30% of men over 35. The remaining 70% experience persistent low energy despite normal testosterone levels (thyroid dysfunction), water retention and mood swings (estrogen excess), or continued body composition deterioration (insulin resistance).
The alternative to TRT is selective androgen receptor modulator monotherapy with compounds like enclomiphene, which blocks estrogen receptors in the hypothalamus to increase endogenous LH and testosterone production. Enclomiphene at 12.5-25 mg daily raises total testosterone by 200-400 ng/dL without suppressing natural production. This preserves fertility and avoids shutdown but caps peak testosterone levels around 600-800 ng/dL and introduces estradiol variability. For men over 35 with baseline testosterone below 400 ng/dL, TRT with the full stack delivers superior symptom resolution and body composition changes compared to enclomiphene.
Peptide-based approaches using kisspeptin or gonadorelin to stimulate GnRH remain experimental with inconsistent dosing data and limited availability. These avoid shutdown but require daily injections and produce unpredictable testosterone elevations. TRT offers reproducible pharmacokinetics and two decades of safety data at physiologic doses.
Common Mistakes
Starting with excessive testosterone dose—200+ mg weekly—creates aromatization management problems that require high-dose AI, crashing estradiol and causing rebound when the user inevitably reduces the AI out of fear. Begin at 150 mg weekly, wait 6 weeks for steady state, measure estradiol, then adjust testosterone or AI based on markers and symptoms.
Using testosterone without monitoring estradiol. At least 40% of men convert aggressively and reach estradiol levels above 50 pg/mL at 150 mg weekly testosterone. These users spend months wondering why they feel worse than before TRT while gaining water weight and losing libido. Check estradiol at week 6 without exception.
Ignoring thyroid function because TSH falls within the standard reference range of 0.5-4.5 mIU/L. TSH above 2.5 mIU/L indicates subclinical hypothyroidism in the context of optimization. Free T3 below mid-range confirms the need for intervention. TRT increases metabolic demand; thyroid function that was adequate at baseline becomes insufficient under enhanced androgen signaling.
Discontinuing the protocol after 8 weeks due to impatience or fear of side effects before reaching steady state or implementing proper mitigation. TRT requires 12 weeks minimum to assess efficacy. Most side effects—water retention, acne, mood swings—resolve with estrogen management, not protocol abandonment.
Relying on total testosterone alone while ignoring free testosterone and SHBG. A man with total testosterone at 900 ng/dL but SHBG at 65 nmol/L has low free testosterone and poor symptom relief. The solution is not more testosterone but rather addressing the elevated SHBG through improved insulin sensitivity and reduced inflammatory load.
Bottom Line
- Start with testosterone enanthate 150 mg weekly split into two doses, anastrozole 0.25 mg twice weekly, and metformin 500 mg twice daily
- Add liothyronine 12.5 mcg twice daily if TSH exceeds 2.5 mIU/L or free T3 is below mid-range
- Target estradiol 20-35 pg/mL; symptoms and quality of life correlate more strongly with estradiol management than testosterone levels
- Full blood panel at week 6, adjust AI or testosterone based on estradiol and free testosterone, repeat at week 12
- HCG at 250 IU three times weekly preserves testicular function; non-negotiable if fertility is a consideration within 5 years